EMA Application withdrawn: Lenalidomide Celgene Europe (lenalidomide) — Celgene Europe Limited

View source ↗

Summary

EMA withdrew thelenalidomide Celgene Europe application for myelodysplastic syndromes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Lenalidomide Celgene Europe (lenalidomide)

Snippet

Status: Application withdrawn. Therapeutic area: Myelodysplastic Syndromes. MAH: Celgene Europe Limited. Decision date: 31/12/2009